To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program and to provide for sickle cell disease research, surveillance, prevention, and treatment.
The bill’s titles are written by its sponsor.
Sponsor and status
115th Congress (2017–2019)
This bill was introduced in a previous session of Congress and was passed by the House on February 26, 2018 but was never passed by the Senate.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
2 Cosponsors (1 Democrat, 1 Republican)
Position statements
What legislators are saying
“Burgess Statement on the Advancement of FDA User Fee Reauthorization and Two Bipartisan Public Health Bills”
—
Rep. Michael Burgess [R-TX26]
(Co-sponsor)
on May 19, 2017
“Bilirakis Applauds Progress on Drug Prices, Public Health Bills”
—
Rep. Gus Bilirakis [R-FL12]
on May 18, 2017
“The Week Ahead - scheduled votes, committee action and other important notes for the week of February 26, 2018”
—
Rep. David Young [R-IA3, 2015-2018]
on Feb 26, 2018
More statements at ProPublica Represent...
What stakeholders are saying
History
|
Jul 16, 2014
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 5124 (113th). |
|
Apr 15, 2015
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 1807 (114th). |
|
May 11, 2017
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
May 18, 2017
|
|
Considered by Health
A committee held a hearing or business meeting about the bill.
|
|
Jun 7, 2017
|
|
Ordered Reported
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee. |
|
Oct 19, 2017
|
|
Reported by House Committee on Energy and Commerce
A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions. |
|
Feb 26, 2018
|
|
Passed House (Senate next)
The bill was passed in a vote in the House. It goes to the Senate next. The vote was by voice vote so no record of individual votes was made. |
H.R. 2410 (115th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 2410. This is the one from the 115th Congress.
This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 2410 — 115th Congress: Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.” www.GovTrack.us. 2017. May 18, 2022 <https://www.govtrack.us/congress/bills/115/hr2410>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
